Searched for
SPECIALTY INJECTABLES MAKER
Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 crSpecialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with a...- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement listThe inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs ...
- Aurobindo Pharma eyes $5-B revenue in 5 yearsAurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialitie...
- Biological E to invest Rs 1800 crore to augment vaccine capacity, injectables, R&DAccording to a press release issued by the state government, the expansion is primarily targeted to ramp up the manufacturing of vaccines a...
- Amneal Pharma to set up plant in GujaratThe NYSE-listed, $2-billion drug maker by sales (2020), which is foraying into India's domestic formulations segment with focus on biologic...
- Amneal to enter Indian formulation mkt, to setup greenfield biologics plant in AhmedabadIn an interview to ET, Chirag Patel, Co-Chief Executive Officer of Amneal said that the company would hit the Indian market with its first ...
- Biological E acquires Akorn India to ramp up vaccine & injectable medicine capacitiesAkorn India, a subsidiary of the US-based Akorn Inc., has a manufacturing plant of 39,000 square metres over a 14-acre campus in Himachal P...
- Prabhudas Lilladher upgrades Lupin to hold, raises target price to Rs 760Hold Lupin Ltd. at a price target of Rs 760.0 .
- Complex generics, biosimilars & specialty to be growth drivers: LupinWhile sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products ...
- Baxter to acquire Claris Injectables for Rs 4,237 crore"The Boards of Directors of both companies have approved the proposed acquisition, which is expected to close in the second half of 2017," ...
- Top PE firms join race for Claris Lifesciences’ US businessThe business is expected to be valued at over $500 million and may also attract interest from a Chinese drugmaker and some Indian pharma co...
- GAVIS Pharma LLC looking to exit Bengaluru-based Wintac LtdGavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...
- Torrent, Dr Reddy’s, Aurobindo, Cipla, Lupin in race to buy SagentValuation is expected to be upwards of $500 million (Rs 3,400 crore), for which large generic drug makers and financial investors like glob...
- Swedish firm Recipharm buys majority stake in Nitin Lifesciences for Rs 671 croreSwedish contract drug manufacturing firm Recipharm has acquired a 74% stake in Nitin Lifesciences, a privately held sterile injectables man...
- Strides completes $1.75 billion sale of Agila Specialties to MylanStrides Arcolab said it has completed the sale of its Agila Specialties division to Mylan Inc for a total consideration of up to $1.75 bill...
- Claris Lifesciences gets USFDA drug approvalClaris Lifesciences Ltd, a parenteral drug company has received drug approval from US drug authorities for hypertension and angina treatmen...
- Mainstay gone, strides in for a rough rideThe company had earlier acquired assets, improved efficiencies and subsequently sold them at attractive valuations.
- Pfizer may value Strides unit at Rs 10,000 crorePfizer's discussions with Strides Arcolab to acquire the latter's unit, Agila Specialties , is at a fairly advanced stage.
- Strides Arcolabs unit sale attracts Novartis, Pfizer & Kohlberg Kravis RobertsGlobal drug-makers including Novartis and Pfizer are among ‘serious bidders’ considering bidding for Bangalore-based Strides Arcolabs injec...
Load More
